Liquid Stable Kit Determines Homocysteine in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Jun 2012 |
A liquid stable homocysteine kit provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is an indicator of a number of disease markers and should be an integral part of a laboratory’s testing menu.
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Latest Clinical Chem. News
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Channels
Molecular Diagnostics
view channel
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








